YUHAN CORPORATION Logo

YUHAN CORPORATION

A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.

000100 | KO

Overview

Corporate Details

ISIN(s):
KR7000100008
LEI:
Country:
South Korea
Address:
서울특별시 동작구 노량진로 74, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Yuhan Corporation, established in 1926, is a leading South Korean pharmaceutical and chemical company. The firm is primarily engaged in the research, development, manufacturing, and sale of a diverse portfolio of products. Its core business segments include Primary & Specialty care, featuring prescription drugs such as the anticancer treatment Lecraza; dietary supplements; household and animal care products; and the contract manufacturing of active pharmaceutical ingredients (APIs). As a pioneering entity in Korea's pharmaceutical sector, Yuhan Corporation is committed to innovation through its advanced R&D capabilities and manufacturing facilities, while also upholding a strong tradition of social responsibility.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.2 KB
2025-09-02 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 35.6 KB
2025-08-27 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 7.7 KB
2025-08-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 72.8 KB
2025-08-26 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-20 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 7.7 KB
2025-08-18 00:00
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
Korean 19.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 5.3 MB
2025-08-01 00:00
Regulatory News Service
신탁계약해지결과보고서
Korean 20.8 KB
2025-07-30 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.5 KB
2025-07-30 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 28.6 KB
2025-07-29 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.0 KB
2025-07-01 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 34.0 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-26 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB

Automate Your Workflow. Get a real-time feed of all YUHAN CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for YUHAN CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for YUHAN CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America
COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America
CGTX
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel
CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America
CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB

Talk to a Data Expert

Have a question? We'll get back to you promptly.